- Delic Holdings Corp works to develop novel solutions for hard-to-treat mental and emotional disorders
- The company’s Ketamine Wellness Centers (“KWC”) clinical subsidiary recently announced the addition of NAD+ (nicotinamide adenine dinucleotide) infusion therapies as a means of boosting natural energy stores and immunity, brain and DNA function, and cell communication
- The NAD+ therapies will launch in six of KWC’s clinics on May 9 — in Jacksonville, Fla.; Houston and Dallas, Texas; Salt Lake City, Utah; Las Vegas, Nev.; and Tucson, Ariz.
- KWC intends to expand the treatment to additional clinics across the country in the coming months
Delic Holdings (CSE: DELC) (OTCQB: DELCF) is devoted to finding solutions for mental ailments — not simply by easing symptoms, but by attacking the root causes of the difficulties utilizing a toolbox of innovative, therapeutic treatments based in psychedelic substances.
The company’s Delic Labs scientific research subsidiary aims to develop IP of the highest quality, while affiliated clinics work to administer the psychedelic treatments under professional management. An educational wing of the company disseminates information that helps people make decisions based on correct principles.
On May 4, Delic announced that six of its clinic locations will launch a specialized therapy that has the potential to boost natural energy stores and immunity, brain and DNA function, and cell communication.
The NAD+ (nicotinamide adenine dinucleotide) infusion therapy is administered intravenously or intramuscularly and has previously shown evidence that such treatments support the creation of new cells, neuropathways, and networks in the brain, which in turn helps patients recover from various mental health conditions, according to the company’s statement (https://ibn.fm/LP9VT).
Those conditions include post-traumatic stress disorder (“PTSD”), suicidality and chronic pain — conditions that gained increased attention after the ravages of World War II but that have still largely been bereft of medical solutions. While psychedelics were once advocated as potential treatments by helping patients to “liberate themselves,” they were generally outlawed between 1969 and 1985 until recently gaining new acceptance among professionals (https://ibn.fm/FBDa9).
“At KWC (Delic’s Ketamine Wellness Centers clinics) we are committed to building on our holistic approach to mental health wellness and pursuing the most effective and suitable treatments to address our patients’ needs,” KWC CEO Kevin Nicholson, who is also Delic’s COO, stated in the May 4 news release. “The introduction of NAD+ infusion therapy to our clinics is a strong complement to ketamine therapy and has benefits for their mental and physical well-being. Moving forward, we are excited to explore new methods of treatments that may support our patients even further on their journey.”
The NAD+ therapies will begin May 9 in Jacksonville, Houston, Salt Lake City, Dallas, Las Vegas and Tucson. KWC plans to introduce the therapies at additional clinics in the coming months.
The existing ketamine therapies use an anesthetic medication that acts as a sedative to help reduce chronic pain, but in dealing with depression under a separate protocol it is also often combined with talk therapy to make it more effective during a dissociative state (https://ibn.fm/MHy5p).
“An unfortunate reality is that it is easier for some ketamine clinics to lead a patient to their treatment room, start their IV, and then monitor patients remotely. At KWC, under no circumstances will we ever leave a patient in a treatment room unattended,” the company’s website states (https://ibn.fm/Lnppx). “A successful treatment experience starts with attentive and compassionate care from a skilled clinician who works with you throughout your infusion.”
For more information, visit the company’s website at www.DelicCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
